EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation

Takuya Tokunaga iD, Yuka Ishihara, Aya Harada Takeda iD, Yuya Tomioka iD, Ayako Nagata iD, Mayuko Kato iD, Takayuki Suetsugu, Keiko Mizuno iD, Kazuhiro Ueda iD, Naohiko Seki iD

Genes · 2026

DOI: 10.3390/genes17091016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Takuya Tokunaga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, MicroRNAs, Pyrimidines, Acrylamides. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: An analysis of microRNA (miRNA) expression signatures in lung adenocarcinoma (LUAD) harboring EGFR mutations revealed that multiple miRNAs, including miR-126-3p, were suppressed in cancer tissues. This study focused on miR-126-3p and aimed to identify therapeutic target genes regulated by miR-126-3p in LUAD harboring EGFR mutations and evaluate their potential for combination therapy with EGFR tyrosine kinase inhibitors.

Methods

The antitumor function of miR-126-3p was analyzed by the ectopic expression of miR-126-3p into LUAD cells with EGFR mutation. The target genes of miR-126-3p were identified through an analysis of the TargetScan, Genecodis 4 and TCGA databases. The Chou–Talalay method was used to determine the potential synergistic effects of selected drug combinations.

Results

The expression of miR-126-3p attenuated the malignant transformation of LUAD cells through targeting the “EGFR tyrosine kinase inhibitor resistance pathway”. We focused on AKT2 among the genes involved in this pathway. Capivasertib was recently approved as the first inhibitor of oncogenic AKT signaling. Therefore, we investigated the effect of combination therapy comprising osimertinib and capivasertib on LUAD cell viability. Combination therapy synergistically reduced cell viability in both PC9 and H1975 cells, with combination index values of 0.61 and 0.14, respectively, at Fa = 0.5.

Conclusions

Our miRNA-based analysis is an excellent strategy for identifying therapeutic targets that enhance the effects of EGFR inhibitors on LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsMicroRNAsPyrimidinesAcrylamidesLung NeoplasmsAdenocarcinoma of LungProto-Oncogene Proteins c-aktPyrrolesHumansIndolesErbB ReceptorsMutationCell Line, TumorProtein Kinase InhibitorsGene Expression Regulation, NeoplasticAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

AKT2EGFR mutationcapivasertibmiR-126-3pmolecular pathwayosimertinib

Substanzen

IndolesAniline CompoundsMicroRNAsPyrimidinesErbB ReceptorsAcrylamidesosimertinibProto-Oncogene Proteins c-aktEGFR protein, humancapivasertib

Autor:innen und Institutionen

  • Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

ORCID-Profile: Takuya Tokunaga, Aya Harada Takeda, Yuya Tomioka, Ayako Nagata, Mayuko Kato, Keiko Mizuno, Kazuhiro Ueda, Naohiko Seki

Förderung

  • Japan Society for the Promotion of Science
  • KAKENHI

Zitieren

APA

Tokunaga, T., Ishihara, Y., Takeda, A. H., Tomioka, Y., Nagata, A., Kato, M., Suetsugu, T., Mizuno, K., Ueda, K., & Seki, N. (2026). AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation. Genes. https://doi.org/10.3390/genes17091016

Vancouver

Tokunaga T, Ishihara Y, Takeda AH, Tomioka Y, Nagata A, Kato M, et al. AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation. Genes. 2026. doi:10.3390/genes17091016

BibTeX
@article{Tokunaga2026,
  author = {Tokunaga, Takuya and Ishihara, Yuka and Takeda, Aya Harada and Tomioka, Yuya and Nagata, Ayako and Kato, Mayuko and Suetsugu, Takayuki and Mizuno, Keiko and Ueda, Kazuhiro and Seki, Naohiko},
  title = {AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17091016}
}
Kostenlos starten →